

**Cancer  
Research &  
Treatment  
Fund, Inc.**



**SPRING/SUMMER 2000**

## **Nancy Brinker To be Inducted into CR&T's Cancer Survivors Hall of Fame**

"Nancy Brinker is one of my heroes. Turning tragedy into courage, this amazing woman created the Komen Foundation from scratch and turned it into a huge nationwide organization dedicated to making the cure of breast cancer not only possible, but highly visible and urgent." A fellow Texan, Dr. Gabriel Hotobagyi of Houston, spoke these words in 1997. He had received the Brinker International Award, which recognizes cancer researchers for significant contributions. Winning the award, he said, was moving because he had known Susan Komen when she was a patient in his institution.

It was after losing Susan to breast cancer in 1980 that Nancy Brinker resolved to fulfill her sister's final request: to crusade against breast cancer. She began with some good friends in her living room, a few hundred dollars and shoebox full of names – and went on to establish the Susan G. Komen Breast Cancer Foundation.

Since its incorporation in 1982 through fiscal 1998, the Foundation has raised more than \$210 million for breast cancer research, education, screening and treatment programs. An international organization, it has a network of more than 40,000 volunteers working through local affiliates

and Komen Race for the Cure events. The Foundation runs an innovative, responsive grant program, with a current portfolio of over \$33.5. In addition to research, it funds breast cancer education, screening and treatment projects for the medically under-served in their own communities.


Brinker served as chairman of the Foundation, supervising all aspects of initial organizational growth. Currently, she serves on the Foundation's




**Nancy Brinker  
Founder, Komen Foundation**

international board of directors. She is actively involved in

*Continued on page 3*



**William R. Johnston  
President and Chief Operating  
Officer  
New York Stock Exchange**



**Richard A. Grasso  
Chairman and Chief Executive  
Officer  
New York Stock Exchange**

### **Cancer Survivors Hall of Fame Installation and Dinner**

**Thursday, October 12, 2000  
The Pierre  
New York City**

**Installing  
Nancy Brinker**

**Honoring  
Richard A. Grasso**

**Dinner Chairman  
William R. Johnston**

For additional information please call Carla Capone at the CR&T Benefit Office at 212.213.1166 or fax at 212.213.4144.

# Young Professionals Stage Mardi Gras

Over 300 people attended the March 1 CR&T Young Professionals Mardi Gras at the Puck Building in New York City. This successful fundraiser featured DJ Scribble of MTV fame at his dual turntables. The sponsored bar and buffet were generous. The evening also included a raffle and silent auction. The success of this event has encouraged the Young Professionals to planning its next Mardi Gras in 2001.



**Welcome!**

The CR&T Young Professionals  
Thank these generous individuals for their help

- Henry Amoroso, Esq.
- Mary Corigliano
- Christine Farby & Matthew Efron
- John Henry
- Rachel & Randy Krupnick
- Dr. Alan A. Manevitz
- Michael Marchassalla
- David Orange
- Samuel Reiken, Esq.
- Richard Salzman
- Hank Seiden
- Steve Spoonamore
- DJ Scribble
- James Viero

Mardi Gras Masquerade

Dr. Richard T. Silver  
and DJ Scribble





(Above) James Babbin, Randy Krupnick, Adam Silver, Nancy Potts, Bradley C. Shaw, Rachel Krupnick, Dr. Richard T. Silver, Doug McCormick, DJ Scribble, Kasia McCormick, Mary Corigliano, and Todd Shaw

(Left) Randy and Rachel Krupnick and Adam Silver

(Below) Todd Shaw, Chairman, CR&T Young Professionals



## Nancy Brinker To be Inducted

*Continued from cover*

strategic planning and the concerns of staff and volunteers. Of special interest is international expansion in Argentina, Germany, Greece and Italy.

She has advocated women's health issues in congressional hearings, served on the 1986 and 1991 National Cancer Panels under Presidents Reagan and Bush, and under Vice President Quayle to monitor research, progress and developments in the fight against breast cancer in 1992. She testified before the United States Democratic Policy Committee's Congressional Cancer Forum, participated in the international Women's Forum. She is a collaborating partner for the National Dialogue on Cancer.

A breast cancer survivor herself, Brinker uses her experience to heighten

understanding of the disease. She is a popular public speaker in demand across the country. She speaks on the importance of patient's rights and medical advancements in breast cancer research and treatment.

Brinker was a signatory and witness to the Treaty of Paris Against Cancer presented at the Palace of Versailles in February 2000 as part of the International Congress of Anticancer Therapy and World Summit Against Cancer. Jacques Chirac, President, Republic of France, presented Brinker with the 200 Cino del Duca Award for exceptional contribution to the field of oncology.

On October 12, 2002, at The Pierre in New York City, Nancy Brinker will be installed into the Cancer Research & Treatment Funds Cancer Survivors Hall of Fame.

(See sidebars for Nancy Brinker's additional awards and corporate and non-profit board service.)

## The Susan G. Komen Breast Cancer Foundation

The Susan G. Komen Breast Cancer Foundation was founded in 1982 by Nancy Brinker to honor the memory of her sister, Susan G. Komen, who died of breast cancer at the age of 36. Eighteen years later, the Foundation is widely recognized as the national leading catalyst in the fight against breast cancer.

The Foundation's stated mission is to eradicate breast cancer as a life-threatening disease by advancing research, education, screening and treatment. As the country's most progressive grassroots organization fighting breast cancer today, the Foundation has more than 35,000 volunteers working through 117 Komen affiliates in communities across the country and pilot affiliates in Argentina, Greece and Italy.

The Komen Race for the Cure series is the largest series of 5K fun/fitness walks in the world. Since its origination in Dallas in 1983, the Race has grown from one local event with 800 participants to a national series of 98 races.

Since its inception, the Foundation has awarded more than 370 national grants totaling more than \$45 million for breast cancer research and outreach projects. It currently supports research at a variety of institutions in four different countries. The national grant program adheres to a peer-review process recognized by the National Cancer Institute.

Komen affiliates across the country fund non-duplicative breast cancer outreach projects for the medically underserved in their local communities,

working with local medical experts and community leaders to conduct comprehensive community needs assessments. Community profiles are used to

establish local grant application and review processes consistent with the Foundation's national standards and its mission.

The Foundation is a source of breast health and breast cancer information for people all over the world. Its web site ([www.breastcancerinfo.com](http://www.breastcancerinfo.com)) provides information about research findings, clinical trials, local outreach programs, volunteer opportunities, and Komen programs and events.

*The Foundation is a source of breast health and breast cancer information for people all over the world.*

# Thalidomide in the Treatment of Cancer

Dr. Richard T. Silver, MD

As our readers know, last year Dr. Judah Folkman – father of angiogenesis – was visiting professor at Cornell Medical College sponsored in part by CR&T. It may be recalled that angiogenesis is the development of blood vessels that supply tumor growth. Dr. Folkman is the most famous and among the first scientists interested in developing a variety of compounds which strangle the blood supply to tumors. We have become particularly interested in the anti-angiogenic factors because of their effect on tumors of the blood system. One that has been of particular interest to us is the drug thalidomide.

Years ago in Europe, where it was very popular, thalidomide was initially used as a sedative and anti-nausea pill during pregnancy. Fortunately, a physician-inspector for the United States Federal Food and Drug Administration did not like some of the data he reviewed and refused to allow the drug to be approved in our country, despite vigorous objec-

tions of its proponents. Thank goodness!

As many of you are aware, limb malformation in newborns was noted from those born of mothers who had taken thalidomide as a sleeping pill during a critical portion of their pregnancy. And some very bright embryologists, neonatologists and others suggested that thalidomide inhibited the blood supply to developing limbs in the fetus. Subsequently, this was found to be correct, an observation supported by a variety of other laboratory studies.

Other clinical effects of thalidomide are of particular interest to those of us in cancer chemotherapy. Thalidomide causes immunosuppression. This was first noted in treating leprosy patients. Most recently, thalidomide has reported to be very active in a disease called multiple myeloma both as a single agent and in combination with other chemotherapy. A colleague, Dr. Bart Bartolagi at the University of Arkansas, first reported this.

Of particular interest for those of you

who surf the Internet is the important role of patients in modern medicine. It was the wife of a patient with myeloma who suggested the use of the thalidomide because of its anti-angiogenic effect which she had read about while looking at potential new agents for the treatment of myeloma. Dr. Bartolagi acknowledged her contribution in the article that appeared in the New England Journal of Medicine in November 1999.

The reason that we have been interested in using thalidomide in the myeloproliferative diseases is because the blood supply of the bone marrow in patients with leukemia is extremely high. If the blood to the leukemic cells could be reduced then growth would be effected. Conceivably thalidomide could be useful with chemotherapeutic agents.

Thalidomide is relatively well tolerated and as one might anticipate, helps the patient get a good nights sleep. In increased dosage, of course, it can cause somnolence, which can be troublesome in some patients. Nevertheless there are analogs of this drug being developed.

## Nancy Brinker

### Recognition and Awards

*Sporting Goods Business*, Woman of the Year  
*Ladies' Home Journal*, 100 Most Important Women of the 20<sup>th</sup> Century  
*Biography Magazine*, 25 Most Powerful Women in America  
 Saloman Smith Barney first Extraordinary Achievement Award  
*American Health Magazine's* 1998 Women's Health Heroes  
 Jefferson Award for Greatest Public Service by a Private Citizen  
 National Breast Cancer Awareness Month Lifetime Achievement Award  
 National Women's Economic Alliance Excellence in Leadership Award  
 Texas Governor's Award for Outstanding National Service  
*Mirabella*, Health Award  
 Texas Women's Hall of Fame

Presidents Volunteer Action Award  
 Republican Women's Leadership Forum 1999  
 Humanitarian of the Year  
 Women in Sports and Events (WISE) 1999 Woman of the Year  
*Feminine Fortunes*, Woman of the Next Millenium Award

### Corporate and Non-Profit Board Activity

(Currently)  
 Board of Directors, Susan G. Komen Breast Cancer Foundation, U.S. Oncology Inc, and Netmarket Group, Inc.  
 National Spokesperson, AstraZeneca Pharmaceuticals  
 Harvard Center for Cancer Prevention Advisory Board  
 National Jewish Coalition Board of Governors  
 New York University Medical School Foundation  
 Breast Health Access for

Women with Disabilities  
 National Surgical Adjuvant Breast Project  
 (Past)  
 Harvard School of Public Health  
 Brain Injury Association  
 National Women's Health Resource Center  
 Women's Health Initiative\*  
 American Cancer Society Breast Cancer Screening Project\*  
 National Coalition of Cancer Survivorship\*  
 National Cancer Institute\*  
 President's Cancer Panel  
 American Cancer Society National Conference on Clinical Trials  
 National Institute of Health\*  
 Women's Leadership Network  
 International Coordinating Council for Cancer Research

\*Advisory Boards

### Cancer Research and Treatment

**Fund, Inc.**, is a non-profit group of physicians, nurses, and other medical professionals dedicated to research for the treatment of cancer and other blood diseases. Richard T. Silver, MD FACP founded CR&T in 1968.

Dr. Silver is Director of the Section of Clinical Oncology Chemotherapy Research at the New York Hospital/Cornell Medical Center and Clinical Professor of Medicine at Cornell University Medical College. He is an Attending Physician at New York Hospital.

Cancer Research & Treatment Fund  
 1440 York Avenue, Suite P4  
 New York, NY 10021

Telephone: (212) 288-6604  
 Fax: (212) 288-7704

Web Site: [www.crt.org](http://www.crt.org)

Richard J. Rose, President

Richard T. Silver, MD FACP,  
 Medical Director

George Kramer, Editor